The AIMAR recommendations for early diagnosis of chronic obstructive respiratory disease based on the WHO/GARD model

Multidisciplinary Respiratory Medicine

Volumn 9, Issue 1, 2014, Pages

  Nardini, Stefano ^a   Annesi Maesano, Isabella ^b,c   Del Donno, Mario ^d   Delucchi, Maurizio ^e   Bettoncelli, Germano ^f   Lamberti, Vincenzo ^g   Patera, Carlo ^h   Polverino, Mario ⁱ   Russo, Antonio ^d   Santoriello, Carlo ^j   Soverina, Patrizio ^k  

^a Vittorio Veneto General Hospital   (Italy)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d G RUMMO HOSPITAL   (Italy)

^e Saluzzo Hospital   (Italy)

^f SIMG Area Respiratoria   (Italy)

^g ULSS 7 Regione Veneto   (Italy)

^h Regione Veneto   (Italy)

ⁱ ASL Salerno   (Italy)

^j Gastroenterology Unit   (Italy)

^k SIMG Area Respiratoria   (Italy)

more..

Author keywords

COPD; Early diagnosis; Guidelines; Prevention; Respiratory diseases

Indexed keywords

ACLIDINIUM BROMIDE; BUDESONIDE PLUS FORMOTEROL; FENOTEROL; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; OXITROPIUM BROMIDE; ROFLUMILAST; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BODY MASS; BRONCHUS OBSTRUCTION; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH SERVICE; HOME CARE; HOSPITALIZATION; HUMAN; HYPERCAPNIA; HYPERTENSION; INCIDENCE; ITALY; LONG TERM OXYGEN THERAPY; LUNG CANCER; MASS SCREENING; NONINVASIVE VENTILATION; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PNEUMONIA; PNEUMOTACHOGRAPH; PREVALENCE; PRIMARY PREVENTION; PULSE OXIMETRY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; SPIROMETRY; UNITED KINGDOM;

EID: 84947804818     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-9-46     Document Type: Review

References (132)

1. http://www.un.org/ga/search/view-doc.asp?symbol=A/66/83&Lang=E.
2. http://whqlibdoc.who.int/publications/2009/9789241597418-eng.pdf.
3. http://www.who.int/gard/publications/GARD%20Book%202007.pdf.
4. Improve healthcare by reducing unnecessary emergency admissions. no 2006/0104, 20 Marzo 2006.
5. Regione Veneto: Allegato "A" a DGR no 68/18, giugno; 2013.
6. Schiarire l'aria: uno studio nazionale sulla bronco pneumopatia cronica ostruttiva. Multidiscip Resp Med 2007, 2(1):19-22.
7. Istituto Superiore di Sanità: In La mortalità per causa in Italia: 1980-2003 e 2006-2008. http://www.iss.it/site/mortalita/Scripts/SelCause.asp.
8. De Marco R., Accordini S, Marcon A., Cerveri I, Antó JM, Gislason T, Heinrich J, Janson C, Jarvis D, Kuenzli N, Leynaert B, Sunyer J, Svanes C, Wjst M, Burney P, European Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011, 183:891-897.
9. Agenzia Nazionale per i Servizi Sanitari Regionali (AGENAS) Broncopneumopatia Cronica Ostruttiva - Linee guida nazionali di riferimento per la prevenzione e la terapia Roma; 2011.
10. Gini R, Francesconi P, Mazzaglia G., Cricelli I, Pasqua A, Gallina P., Brugaletta S, Donato D, Donatini A., Marini A, Zocchetti C, Cricelli C., Damiani G, Bellentani M, Sturkenboom M.C., Schuemie MJ: Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of populationestimates with general practice databases and National survey. BMC Public Health 2013, 13:15.
11. Viegi G, Pedreschi M, Pistelli F., Di Pede F, Baldacci S, Carrozzi L., Giuntini C: Prevalence of airways obstruction in a general population. European Respiratory Society vs American Thoracic Society definition. Chest 2000, 117(5 Suppl 2):339S-345S.
12. Soverina P e Gruppo SIMG-Pneumo: La problematica previdenziale della broncopneumopatia cronica ostruttiva. In http://www.simg.it/documenti/rivista/2012/01-2012/8.pdf.
13. Lindberg A, Jonsson AC, Rönmark E, Lundgren R., Larsson LG, Lundbäck B: Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005, 72:471-479.
14. Lindberg A, Bjerg-Bäcklund A, Rönmark E, Larsson LG, Lundbäck B: Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking. Report from the Obstructive Lung disease in Northern Sweden Studies. Respir Med 2006, 100:264-272.
15. Dekhuijzen PN: The Confronting COPD International Survey: patients hardly know they have COPD. Eur Respir J 2002, 20:793-794.
16. Beniwal S, Sharma BB, Singh V: What we can say: disease illiteracy. J Assoc Physicians India 2011, 59:360-364.
17. Murray CJ, Lopez AD: Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of disease Study. Lancet 1997, 349:1347-1352.
18. Shahab L, Jarvis MJ, Britton J, West R: Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006, 61:1043-1047.
19. Nardini S, De Benedetto F, Sanguinetti CM, Donner C.F., per AIMAR (Associazione Scientifica Interdisciplinare per lo studio delle malattie Respiratorie): Il Progetto "SOS Respiro" di AIMAR. I risultati del primo progetto Italiano globale su COPD ed asma. Multidiscip Resp Med 2007, 2(4):16-23.
20. Danielsson P, Ólafsdóttir IS, Benediktsdóttir B, Gíslason T, Janson C: The prevalence of chronic obstructive pulmonary of disease in Uppsala, Sweden-the Burden of Obstructive Lung disease (BOLD) study: cross-sectional population-based study. Clin Respir J 2012, 6(2):120-127
21. Rycroft CE, Heyes A, Lance L., Becker K: Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis 2012, 7:457-494.
22. Halbert RJ, Isonaka S, George D., Iqbal A: Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003, 123(5):1684-1692
23. Halbert RJ, Natoli JL, Gano A, Badamgarav E., Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28(3)523-532.
24. Lindberg A, Eriksson B, Larsson L.G., Rönmark E, Sandström T, Lundbäck B: Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006, 129(4):879-885
25. http//www.patientsCOPD.it/pages/giornataMonofaleCOPD/download/Bettoncelli.pdf.
26. Lusuardi M, Orlandini D, Han M.K., Martinez FJ: Underutilization of spirometry for the diagnosis of COPD. Chest 2008, 133:313-314
27. Lusuardi M, Blasi F, Terzano C., Cricelli C, Crispino N, Comarella L., De Benedetto F, Sanguinetti CM, Allegra L, Donner CF: Standards of care and clinical predictors in patients hospitalised for a COPD exacerbation - The Italian SOS Study (Stratification Observational Study). Monaldi Arch Chest Dis 2009, 71: 4, 153-160.
28. Piperno D, Huchon G, Pribil C., Boucot I, Similowski T: The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003, 97(Suppl C)S33-S42.
29. British Thoracic Society: The Burden of Lung Diseases. 2007. In http://www.brit-thoracic.org.uk/Portals/0/Library/BTS%20Publications/burden-of-lung-ofsease.pdf.
30. http://www.cesfar.it/farmacoeconomia/3-analisi-economica-dei-costi-correlati-alla-gestionedei pazienti in ossigeno terapia domiciliare a lungo termine (OTLT) con o senza monitoraggio telemetrico domiciliare.html.
31. In http://www.rssp.salute.gov.it/rssp2011/paginaParagrafoRssp2011jsp?setion=analisi&capitolo=quadro&id=3149).
32. In 10. http//www.gov.uk/government/uploads/system/uploads/attachment-data/file/213840/dh-113279.pdf.
33. In http://www.salute.gov.it/imgs/C-17-pubblicazioni-1206-allegato.pdf.
34. In http://www.salute.gov.it/imgs/C-17-pubblicazioni-1893-allegato.pdf.
35. In http://www.aimarnet.it/wordpress/wp-content/uploads/2013/02/ManagementCOPD.pdf.
36. In www.agenas.it/images/agenas/pnlg/BPCO.pdf.
37. In http://www.iss.it/binary/fumo/cont/carte-del-risk-COPD-e-TaP.pdf.
38. In http://drfosterintelligence.co.uk/wp-content/uploads/2013/02/Hospital-Guide-2012.pdf).
39. In http://www.who.int/quantifying-ehimpacts/publications/preventingofsease.pdf.
40. In http://www.who.int/fctc/en/index.html.
41. In http://www.who.int/fctc/reporting/progress-report-final.pdf
42. In http://www.ccm-network.it/documenti-Ccm/convegni/SANIT/materiali2008/25.6/1-Promotion-salute-Galeone.pdf
43. In http://www.epicentro.iss.it/temi/materno/rapporto-europa.asp.
44. In http://www.salute.gov.it/imgs/C-17-pubblicazioni-1454-allegato.pdf.
45. Miravitlles M, de la Roza C, Morera J, Montemayor T, Gobartt E, Martín A, Alvarez-Sala JL: Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med 2006, 100(11):1973-1980.
46. Rabe KF, Hurd S, Anzueto A., Barnes PJ, Buist SA, Calverley P, Fukuchi Y., Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J, Global Initiative for Chronic Obstructive Lung Ofsease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
47. Van Schayck C.P., Loozen JMC, Wagena E, Akkermans R.P., Wesseling GJ: Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002, 324:1370.
48. Tønnesen P: Smoking cessation and COPD. Eur Respir Rev 2013, 22(127):37-43.
49. Alderson SL, Foy R, Glidewell L., McLintock K, House A: How patients understand depression associated with chronic physical disease - a systematic review. BMC Fam Pract 2012, 13:41.
50. Petty TL: Definitions, causes, course, and prognosis of chronic obstructive pulmonary disease. Respir Care Clin N Am 1998, 4:345-358.
51. Rudolf M: The reality of drug use in COPD: the European perspective. Chest 2000, 117(2 suppl):29S-32S.
52. Calverley PM, Nordyke RJ, Halbert R.J., Isonaka S., Nonikov D: Development of a population-based screening questionnaire for COPD. COPD 2005, 2(2):225-232.
53. van Schayck C.P., Halbert RJ, Nordyke R.J., Isonaka S., Maroni J, Nonikov D: Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting. Respirology 2005, 10(3):323-333.
54. Freeman D, Nordyke RJ, Isonaka S, Nonikov D.V., Maroni JM, Price D, Halbert RJ: Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005, 99(10):1311-1318.
55. Mapel DW, Frost FJ, Hurley J.S., Petersen H., Roberts M, Marton JP, Shah H: An algorithm for the identification of undiagnosed COPD cases using administrative claims data. J Manag Care Pharm 2006, 12(6):457-465.
56. Price DB, Tinkelman DG, Nordyke R.J., Isonaka S., Halbert RJ, COPD Questionnaire Study Group: Scoring system and clinical application of COPD diagnostic questionnaires. Chest 2006, 129(6):1531-1539.
57. Nelson SB, LaVange LM, Nie Y, Walsh J.W., Enright PL, Martinez FJ, Mannino DM, Thomashow BM: Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general population. Chest 2012, 142(2):358-366.
58. Hegewald MJ, Lefor MJ, Jensen R.L., Crapo RO, Kritchevsky SB, Haggerty CL, Bauer D.C., Satterfield S., Harris T: Peak expiratory flow is not a quality indicator for spirometry: peak expiratory flow variability and FEV1 are poorly correlated in an elderly population. Chest 2007, 131:1494-1499.
59. In http://www.drive4copd.org/AreYouAtRisk/TaketheScreener.aspx.
60. Martinez FJ, Raczek AE, Seifer F.D., Conoscenti CS, Curtice TG, D'Eletto T, Cote C, Hawkins C., Phillips AL, COPD-PS Clinician Working Group: Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD 2008, 5(2):85-95. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430173/pdf/lcpd5-85.pdf.
61. Dirven JA, Tange HJ, Muris J.W., van Haaren KM, Vink G, van Schayck OC: Early detection of COPD in general practice: patient or practice managed? A randomised controlled trial of two strategies in different socioeconomic environments. Prim Care Respir J 2013, 22(3):331-337.
62. Stratelis G, Jakobsson P, Molstad S., Zetterstrom O: Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br J Gen Pract 2004, 54(500):201-206.
63. Zuccaro P, Pichini S, Mortali C., Pacifici R, Viegi G, Baldacci S., Angino A, Martini F, Borbotti M., Scognamiglio A, Simoni M, Silvi P., DiPede F, Carrozzi L, Porta D., Simonato L, Crispo A, Merletti F, Forastiere F: Fumo e patologie respiratorie: le carte del rischio per COPD e tumore al polmone. Multidiscip Resp Med 2007, 2:14-21.
64. In www.iss.it/binary/fumo4/cont/carte-del-rischio-BPCO-e-TaP.pdf.
65. In http://www.salute.gov.it/imgs/C-17-pubblicazioni-1891-allegato.pdf.
66. Ferro A, Cinquetti S, Moro A., Siddu A, Trimarchi A, Penon M.G., Pavan PP, Camillotto R, Rossetto L, Volpe V., Zevrain S, Brusaferro S: Prevenire le patologie cardiovascolari attraverso un modello di valutazione proattiva del rischio (screening) applicabile ad ampie fasce di popolazione. Risultati della prima fase del progetto. Epidemiologia e Prevenzione 2013. in press.
67. Cawley MJ, Moon J, Reinhold J., Willey VJ, Warning II WJ: Spirometry: tool for pharmacy practitioners to expand direct patient care services. J Am Pharm Assoc (2003) 2013, 53(3):307-315.
68. Miller MR, Hankinson J, Brusasco V., Burgos F, Casaburi R, Coates A., Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338.
69. Vandevoorde J, Verbanck S, Schuermans D., Kartounian J, Vincken W: FEV1/ FEV6 and FEV6 as an alternative for FEV1/FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest 2005, 127:1560-1564.
70. Korhonen H, Remes ST, Kannisto S, Korppi M: Hand-held turbine spirometer: agreement with the conventional spirometer at baseline and after exercise. Pediatr Allergy Immunol 2005, 16(3):254-257.
71. Schermer TR, Verweij EH, Cretier R, Pellegrino A., Crockett AJ, Poels PJ Accuracy and precision of desktop spirometers in general practices. Respiration 2012, 83(4)344-352.
72. Ofrksen A, Madsen F, Pedersen O.F., Vedel AM, Kok-Jensen A: Long term performance of a hand held spirometer. Thorax 1996, 51:973-976
73. Malmberg LP, Hedman J, Sovijärvi AR: Accuracy and repeatability of a pocket turbine spirometer: comparison with a rolling seal flow-volume spirometer. Clin Physiol 1993, 13(1):89-98.
74. Enright PL: How to make sure your Spirometry Tests are of good quality. Respir Care 2003, 48(8):773-776.
75. Dowson LJ, Yeung A, Allen MB: General practice spirometry in North Staffordshire. Monaldi Arch Chest Dis 1999, 54(2):186-188
76. Bracci M, Strafella E, Croce N., Staffolani S, Carducci A, Verani M., Valentino M, Santarelli L: Risk of bacterial cross infection associated with inspiration through flow-based spirometers. Am J Infect Control 2011, 39(1)50-55
77. Lusuardi M, De Benedetto F, Paggiaro P, Sanguinetti C.M., Brazzola G., Ferri P, Donner CF: A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. Chest 2006, 129(4):844-852.
78. Enright P: The use and abuse of office spirometry. Prim Care Respir J 2008, 17(4):238-242.
79. Enright P: Provide GPs with spirometry not spirometers. Thorax 2008, 63(5)387-388.
80. Nardini S, Cicchitto G, De Benedetto F, Donner CF, Polverino M, Sanguinetti C.M., Visconti A: Audit sull' appropriatezza nell'assistenza integrata della BPCO. Il progetto "ALT-BPCO". Multidiscip Resp Med 2012, 7(5-6):I-XII.
81. Culver BH: How Should the Lower Limit of the Normal Range Be Defined? Respir Care 2012, 57:136-145.
82. Pellegrino R, Viegi G, Brusasco V., Crapo RO, Burgos F, Casaburi R, Coates A., van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J 2005,26:948-968
83. In http://www.goldcopd.it/traduzioni2011/GOLDREPORT2011Ita.pdf.
84. Celli BR, Halbert RJ, Isonaka S, Schau B: Population impact of different definitions of airway obstruction. Eur Respir J 2003, 22(2):268-273
85. Mohamed Hoesein F.A., Zanen P, Lammers JW: Lower limit of normal or FEV1/FVC<0.70 in diagnosisng COPD: an evidence-based review. Respir Med 2011, 105(6):907-915.
86. National Institute for Clinical Excellence (NICE) Clinical Guideline Centre: Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care Update Guideline; 2011 72-74.
87. Nishimura K, Izumu T, Tsukino M., Oga T: Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002, 121:1434-1440.
88. Celli BR, Cote CG, Marin J.M., Casanova C., Montes de Oca M, Méndez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
89. Anzueto A, Leimer I, Kesten S: Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J COPD 2009, 4:245-251
90. Sullivan SD, Buist AS, Weiss K: Health outcome assessment and economic evaluation in COPD: challenges and opportunities. Eur Respir J 2003, 21(suppl. 41):1s-3s.
91. Effing T, Monninkhof EEM, van der Valk PD, van der Palen J, van Herwaarden CL, Partridge MR, Walters EH, Zielhuis GA: Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007, 4:CD002990. doi:10.1002/14651858. CD002990.pub2.
92. Adams SG, Smith PK, Allan P.F., Anzueto A., Pugh JA, Cornell JE: Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med 2007, 167(6):551-561.
93. Rice KL, Dewan N, Bloomfield H.E., Grill J., Schult TM, Nelson DB, Kumari S, Thomas M., Geist LJ, Beaner C, Caldwell M, Niewoehner DE: Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010, 182(7):890-896.
94. Walters JAE, Turnock AC, Walters E.H., Wood-Baker R: Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010, 5:CD005074. doi:10.1002/14651858. CD005074.pub3.
95. McLean S, Nurmatov U, Liu JLY, Pagliari C, Car J., Sheikh A: Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, 7:CD007718. doi:10.1002/14651858.CD007718.pub2.
96. Koff PB, Jones RH, Cashman J.M., Voelkel NF, Vanofvier RW: Proactive integrated care improves quality of life in patients with COPD. Eur Respir J 2009, 33(5):1031-1038.
97. Clark NM, Dodge JA, Partridge M.R., Martinez FJ: Focusing on outcomes: making the most of COPD interventions. Int J Chron Obstruct Pulmon Dis 2009, 4:61-77.
98. Lareau SC, Yawn BP: Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:401-406.
99. Yawn BP, Colice GL, Hodder R: Practical aspects of inhaler use in the management of chronic obstructive pulmonary Disease in the primary care setting. Int J Chron Obstruct Pulmon Dis 2012, 7:495-502.
100. Tønnesen P, Carrozzi L., Fagerstroem KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G., Lazzaro C, Campell IA, Dagli E, West R: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007, 29:390-417.
101. Górecka D., Bednarek M, Nowiński A, Pus̈cińska E, Goljan-Geremek A, Zieliński J: Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003, 123(6):1916-1923.
102. Stratelis G, Mölstad S, Jakobsson P., Zetterström O: The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006, 24(3):133-139.
103. Fiore M, Jaen CR, Baker T.B., Bailey WC, Benowitz N, Curry SJ, Dorfman S.F., Froelicher ES, Goldstein MG, Healton CG, Henderson P.N., Heyman RB, Koh HK, Kottke TE, Lando H.A., Mecklenburg RE, Mermelstein RJ, Mullen PD, Orleans C.T., Robinson L., Stitzer ML, Tommasello AC, Villejo L, Wewers ME, Murray EW, Bennett G, Heishman S, Husten C, Morgan G, Williams C, Christiansen BA, Piper ME, Hasselblad V, Fraser D, Theobald W, Connell M, Leitzke C: Treating tobacco use and dependence: 2008 update. U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008, 53:1217-1222.
104. Guida ai servizi territoriali per la cessazione dal fumo of tabacco (aggiornamento 2012). A cura dell'Osservatorio Fumo, Alcol e Droga 2013. http://www.iss.it/publ/index.php?lang=1&id=2707&tipo=7.
105. Hughes JR, Carpenter MJ: The feasibility of smoking reduction: an update. Addiction 2005, 100(8):1074-1089.
106. Lindson-Hawley N., Aveyard P, Hughes JR: Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012, 11:CD008033.
107. Moore D, Aveyard P, Connock M., Wang D, Fry-Smith A, Barton P: Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009, 338:b1024.
108. 1 - a review. Regul Toxicol Pharmacol 2013, 67:372-381.
109. Nardini S, Pacifici R: E-cigarettes, smokers and health policies. Monaldi Arch Chest Dis 2013, 79(1):6-7.
110. Bateman E, Vogelmeier C, Chen H., Banerji D: Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily Salmeterol/ Fluticasone Combination: The ILLUMINATE Study. Chest 2014, 145(3 Suppl):409A. doi:10.1378/chest.1824338.
111. Wedzicha J, Ficker J, Fowlertaylor A., D'Andrea P, Arrasate C, Chen H., Banerji D: Once-Daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK Study. Chest 2014, 145(3 Suppl):427A. doi:10.1378/chest.1 824414.
112. Cosio BG, Tsaprouni L, Ito K., Jazrawi E, Adcock IM, Barnes PJ: Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200:689-695
113. Ancochea J, Gómez García T, de Miguel DJ: Hacia un tratamiento individualizado e integrado del paciente con EPOC. Arch Bronconeumol 2010, 46(Suppl 10):14-18.
114. Collins PF, Stratton RJ, Elia M: Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Clin Nutr 2012, 95:1385-1395.
115. http://www.epicentro.iss.it/problemi/obesita/pdf/territorio/lombardia/milano/Manuale%20WL%20small.pdf.
116. Nici L, Donner C, Wouters E., Zuwallack R, Ambrosino N, Bourbeau J., Carone M, Celli B, Engelen M., Fahy B, Garvey C, Goldstein R., Gosselink R, Lareau S, MacIntyre N., Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T: ATS/ERS Pulmonary Rehabilitation Writing Committee: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173(12):1390-1413
117. Ries AL, Bauldoff GS, Carlin B.W., Casaburi R., Emery CF, Mahler DA, Make B, Rochester C.L., Zuwallack R., Herrerias C: Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131(suppl 5)4S-42S.
118. Puhan MA, Gimeno-Santos E, Scharplatz M., Troosters T, Walters EH, Steurer J: Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011,10:CD005305.
119. Personal Observations.
120. http://www.isde.it/iniziative/2009/Novembre-Salsomaggiore/4/Corrado%20presentation.pdf.
121. McCurdy BR: Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser 2012, 12:1-65
122. GARD-Italy: La continuità assistenziale: Broncopneumopatia Cronica Ostruttiva (COPD). Roma: 2011. www.salute.gov.it/imgs/C-17-pubblicazioni-1893-allegato.pdf.
123. Macintyre NR: Chronic critical illness: the growing challenge to health care. Respir Care 2012, 57(6):1021-1027.
124. American Thoracic Society Documents Statement on Home Care for Patients with Respiratory Disorders. Am J Respir Crit Care Med 2005, 171:1443-1464.
125. http://www.siaarti.it/documenti/pdf-doc/file-15.pd.
126. Legge n°38 del 2010 "Disposizioni per garantire laccesso alle cure palliative e alla terapia del dolore"-Intesa Stato-Regioni del 25 luglio 2012 Requisiti minimi organizzativi per laccreditamento delle reti di cure palliative e di terapia del dolore
127. Lanken PN, Terry PB, DeLisser H.M., Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski R.A., Osborne ML, Prendergast TJ, Rocker G, Sibbald WJ†, Wilfond B, Yankaskas JR, on behalf of the ATS End-of-Life Care Task Force: An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses. Am J Respir Crit Care Med 2008, 177:912-927.
128. Murray SA, Kendall M, Boyd K., Sheikh A: Illness trajectories and palliative care. BMJ 2005, 330:1007-1011
129. Claessens MT, Lynn J, Zhong Z., Desbiens NA, Phillips RS, Wu AW, Harrell FE Jr, Connors AF Jr: Dying with lung cancer or chronic obstructive pulmonary Disease: insights from SUPPORT. Study to understand prognoses and preferences for outcomes and risks of treatments. J Am Geriatr Soc 2000, 48:S146-S153.
130. Carlucci A, Guerrieri A, Nava S: Palliative care in COPD patients: is it only an end-of-life issue? Eur Respir Rev 2012, 21(126)347-354.
131. Goodridge DM, Marciniuk DD, Brooks D, van Dam A, Hutchinson S, Bailey P., Baxter S, Dorasamy P, Dumont S., Hassan S, Hernandez P, Kerigan A., Rocker G, Wilson D, Young J: End-of-life care for persons with advanced chronic obstructive pulmonary disease: report of a national interdisciplinary consensus meeting. Can Respir J 2009, 16(5):e51-e53.
132. Freeman D, Price D: ABC of chronic obstructive pulmonary disease. Primary care and palliative care. BMJ 2006, 333:188-190.